EyePoint Pharmaceuticals shares fell more than 26% in premarket activity Monday after the company said a trial of its potential diabetes treatment Duravyu failed to meet the primary endpoint of.
On Monday, EyePoint Pharmaceuticals Inc. EYPT announced the topline results of its Phase 2 PAVIA trial evaluating Duravyu (vorolanib intravitreal insert),…
EyePoint reports Duravyu trial fail, raising questions fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $19.74, but opened at $13.89. EyePoint Pharmaceuticals shares last traded at $12.99, with a volume of 4,364,816 shares traded. Analyst Upgrades and Downgrades A number of equities research analysts have […]